Sunesis Pharmaceuticals Inc. (SNSS) and Royalty Pharma announced after the close Thursday that Royalty Pharma has agreed to pay Sunesis $25 million, under certain circumstances related to the successful development of Sunesis' lead product candidate vosaroxin, to acquire a royalty on future worldwide net sales of vosaroxin.
Sunesis Pharmaceuticals gapped up at the open Friday and rose sharply in early trade. The stock has taken out the highs of the morning in the last few minutes and is now up 0.55 at $3.03 on above average volume. Sunesis has broken out of a 3-week range and is now challenging the highs of the year, trading at over a 9-month high.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.